Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
Channelopathy-related SCN10A gene variants predict cerebellar dysfunction in multiple sclerosis.
Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.
Multiple sclerosis in 2014: Progress in MS-classification, mechanisms and treatment.
Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS.
Monomethyl fumarate augments NK cell lysis of tumor cells through degranulation and the upregulation of NKp46 and CD107a.
Combination therapy in patients with relapsing-remitting multiple sclerosis (MS) CombiRx
Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study.
Comparative effectiveness of early Natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
Tolerability and Pulmonary Pharmacodynamic Effects During Treatment Initiation of Once-Daily Oral Fingolimod in Subjects With Moderate Asthma.
Genentech and Biogen Idec announce top-line results from a Phase II/III clinical trial of Rituxan in primary-progressive multiple sclerosis
Myelin Gordon Research Conference
Infectious mononucleosis at the United States Military Academy. A prospective study of a single class over four years.
Optical coherence tomography and neurodegeneration: are eyes the windows to the brain?
Current and future immunotherapy targets in autoimmune neurology.
Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
Mitoxantrone: benefits and risks in multiple sclerosis patients.
Genpharm and Genzyme Aubagio ® agreement for the MENA region
Radiologically isolated syndrome: 5-year risk for an initial clinical event.
Multiple sclerosis and risk of young-adult-onset Hodgkin lymphoma.
Protective effects of monomethyl fumarate at the inflamed blood-brain barrier.
Headache in relapse and remission phases of multiple sclerosis: A case-control study.
Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs.
Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS.
Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis: a prospective, non-randomized pilot study.

Pages